

Nemera announces that Novelia[®], its new preservative-free multidose eyedropper, is now used to dispense ophthalmic drops across 4 continents.

PRESS RELEASE
La Verpillière, April 2015

"There is no limit to Nemera's ambition to serve patients. We already market devices in over 40 countries for millions of users. We'll keep investing in new products and in state-of-the-art manufacturing equipment, to help even more patients with high quality devices all over the world."

Marc Haemel, CEO

Nemera in figures:

- 4 plants in Europe and the USA

Over:

- 1,300 employees

- 30,000 sq. meters of manufacturing clean rooms

- 50 engineers and experts working in our innovation center.

Attached documents:

- Novelia product picture

photos credit Nemera – Document not legally binding

Nemera ©2015

As of today, Novelia[®] is the **only preservative-free multidose system commercialized on the US market.**

Preservatives have been shown to be harmful to the eye and can lead patients to discontinue or skip treatment to avoid irritation and discomfort.

The new multidose ophthalmic packaging Novelia[®] **avoids the need for preservatives in the drug by preventing contamination** of unpreserved formulations.

Novelia[®] represents a major innovation in ophthalmic drug delivery by providing a **preservative-free alternative for chronic treatments in a patient-friendly package.**

Novelia[®] has been well accepted by patients in **over 15 countries worldwide**, including the US, European, Latin American and Asian countries. It is used as for packaging **drug products** as well as **medical devices.**

The key benefit for patients is that it can be used as a 'classic' multidose eyedropper. This device is able to **calibrate droplets**, which improves compliance. Its **blue tip** allows a better precision when targeting the eye and bottles are easy to squeeze. Novelia[®] is also **more sustainable and affordable than unit-doses**, and easier to carry.

For ophthalmic pharmaceutical companies, Novelia[®] offers major advantages:

- **100% controlled and safe** thanks to its patented PureFlow[™] technology
- Functional with suspensions and solutions up to high viscosities
- Large **range of bottles**
- Compatible with most **existing filling lines** (screw cap)
- Simplified manufacturing process thanks to **preassembled cap and nozzle**

The key requirement for such a device is **microbiological sterility**; Novelia[®] has been tested and confirmed for content sterility and drop non-contamination for treatment duration (90 days).

Novelia[®] represents a major innovation in ophthalmic drug delivery device by providing patients with a **preservative-free alternative for chronic treatments, with a patient-friendly package.**

Press contact

Fanny Sellier
Global Category Manager, Ophthalmics
+33 4 74 94 92 99
+33 7 86 09 52 48
fanny.sellier@nemera.net

Find Nemera on the web at www.nemera.net

Nemera is one of the world leaders in the design, development and manufacturing of drug delivery solutions. Its expertise covers all five modes of delivery: ophthalmic (preservative-free droppers), nasal, buccal, auricular (sprays, pumps, etc.), pulmonary (inhalers), dermal and transdermal (dispensers), parenteral (injectors, pens, safety devices). Nemera provides solutions for the pharmaceutical industry, including standard innovative products, development of custom devices and contract manufacturing.